| PRISM Stock Indexes | Current Value | % Change (Daily) | % Change (Inception) | Most Active | Top % Gainers | Top % Losers |
|---|---|---|---|---|---|---|
| Cannabis | $41.20 | 0.1% | -58.8% | SNDL 72,577 | TLRY 6.636% | CLVR -4.369% |
| EV | $60.20 | -1% | -39.8% | NKLA 12,007 | IDEX 6.038% | FUV -8.509% |
| Gene Therapy | $61.00 | -0.1% | -39.0% | BLUE 6,577 | WVE 13.697% | PGEN -9.883% |
| MedDevices | $175.70 | 0.5% | 75.7% | ATRS 5,230 | MLSS 14.152% | OBLN -5.864% |
| MedDiagnostics | $105.20 | 1.6% | 5.2% | OPK 4,888 | THMO 52.121% | TTOO -13.28% |
| Solar | $84.30 | -1.4% | -15.7% | HYSR 4,805 | OEG 2.348% | DQ -5.397% |
| Uranium | $72.30 | -0.9% | -27.7% | UEC 15,858 | NXE 0.286% | LEU -2.347% |
| Vaccines & Cell Therapy | $230.00 | 0.5% | 130.0% | SRNE 10,417 | MESO 10.769% | APDN -3.884% |
| Web 3.0 | $40.40 | -3.9% | -59.6% | MARA 11,802 | SNII 3.33% | PBTS -13.688% |
The waiver allows the sale in 34 Texas counties of higher-volatility, winter-grade gasoline. The Biden administration has released emergency oil stocks and is considering lifting…
[Read More]
The modern investor needs trusted, relevant information, delivered quickly and concisely. CEO3in60 provides a platform for management to succinctly share their company’s value proposition in their own words. We take the CEOs of the most dynamic up and coming companies and put them in front of the camera to provide you with the top three reasons why you should be paying attention to their business, all in less than sixty seconds.
Asensus Surgical (NYSE American: ASXC) is leading the digital surgical market with Performance-Guided Surgery™, which enhances the work of surgeons using state-of-the-art robotics, augmented intelligence and machine learning. Shameze Rampertab, Chief Financial Officer at Asensus, outlines three value drivers for investors that will have the market paying attention in the coming months.
Soligenix (NASDAQ: SNGX) is developing and commercializing products to treat rare diseases in oncology and dermatology where there is an unmet medical need. Chris Schaber, President and CEO of Soligenix, Inc. spends one minute outlining three value drivers that will have investors
Read more about Soligenix, Inc.
Biotechnology company, Oxford BioDynamics (AIM:OBD), is poised for successful commercialization of its precision medicine tests for oncology.
Any seasoned investor will tell you that investing in biotechnology companies comes with an exhilarating balance of risk and reward. If a company is successful in getting its products to market, there is potential for significant investment gains. The complex nature of biotech, and the highly regulated environment in which it operates, can make it difficult for investors to assess the probability of a company’s success.
How do investors measure value in biotechs? The first element investors typically consider is a company’s technology. Is it promising? Is it a discovery made by a well-known and respected institution? Will it solve a problem or change lives for the better? Does it have a good chance of achieving commercial success?
A second measure of value for many investors, often including the most seasoned investors, is a significant market opportunity and a compelling story. OBD’s story is focused on improving outcomes for cancer patients, but also features value drivers – such as its partnerships with leading institutions, collaborations with pharma, strong technology portfolio, commercially available tests for precision medicine and a unique 3D genomic knowledgebase – that will pique investor interest.
The Japanese Yen has been hitting historic lows against the US Dollar over the last few months. White the trend remains down, there are some signs of at least a short-term bottom forming and it may be an opportunity to either lighten up a short position or establish a modest long position with some caution.
